PHIO Phio Pharmaceuticals Corp.

Nasdaq phiopharma.com


$ 1.41 $ -0.15 (-9.49 %)    

Thursday, 13-Nov-2025 19:54:05 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 1.43
$ 1.58
$ 1.37 x 3
$ 1.56 x 10
-- - --
$ 0.97 - $ 9.79
773,128
na
15.39M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-22-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-27-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-26-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-10-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-30-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 phio-pharma-q3-eps-044-misses-040-estimate

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40)...

 phio-pharma-secures-134m-through-warrant-exercises-covering-566m-shares-including-reduced-205-pricing-on-465m-shares

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr...

 why-is-phio-pharmaceuticals-stock-soaring-today

Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medica...

 phio-pharma-reports-100-tumor-clearance-in-final-dose-group-of-skin-cancer-trial

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...

 phio-pharma-to-present-update-on-proprietary-intasyl-sirna-technology-and-progress-on-on-going-clinical-trial-with-lead-compound-ph-762-for-treatment-of-skin-cancers

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...

 phio-pharma-to-present-ph-762-intasyl-sirna-skin-cancer-trial-progress-and-strategic-outlook-at-life-sciences-future-conference-sept-25-26-2025

Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prus...

 phio-pharmaceuticals-to-discuss-strategy-for-ph-762-skin-cancer-drug-at-investor-conference

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its propri...

 phio-pharmaceuticals-has-been-issued-canadian-patent-number-3027780-titled-reduced-size-self-delivering-rnai-compounds

https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3027780/summary.html

 hc-wainwright--co-reiterates-buy-on-phio-pharma-maintains-14-price-target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.

 phio-pharma-q2-eps-045-misses-036-estimate

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36)...

 phio-pharmaceuticals-announces-25m-in-gross-proceeds-from-exercise-of-928596-warrants-at-200-and-2485-per-share-and-issues-1857192-new-unregistered-warrants-at-2485

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr...

 phio-pharmaceuticals-reports-complete-tumor-clearance-in-cscc-patient-and-partial-response-in-stage-4-merkel-cell-carcinoma-in-ongoing-ph-762-phase-1b-trial

Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cel...

 hc-wainwright--co-reiterates-buy-on-phio-pharma-maintains-14-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION